BiotechTube

4D-710

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cystic Fibrosis Lung

Conditions

Cystic Fibrosis Lung

Trial Timeline

Mar 29, 2022 → Jun 1, 2031

NCT ID
NCT05248230

About 4D-710

4D-710 is a phase 2 stage product being developed by 4D Molecular Therapeutics for Cystic Fibrosis Lung. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05248230. Target conditions include Cystic Fibrosis Lung.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05248230Phase 2Recruiting

Competing Products

20 competing products in Cystic Fibrosis Lung

See all competitors
ProductCompanyStageHype Score
VX-522 mRNA therapy + IVAModernaPhase 1/2
38
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
44
Enfortumab VedotinAstellas PharmaPhase 2
52
CefiderocolShionogiApproved
85
LenvatinibEisaiPhase 2
52
Lenvatinib + PembrolizumabEisaiPhase 2
52
CREONAbbVieApproved
85
Pancrelipase + PancrelipaseAbbVieApproved
85
Creon IR + Creon® (DR/GR)AbbViePhase 2
52
ABBV-CLS-628 + PlaceboAbbViePhase 2
52
Elagolix + PlaceboAbbViePhase 2
52
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222AbbViePhase 2
52
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119AbbViePhase 2
52
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
77
AZD5634 for inhalation + AZD5634 for infusionAstraZenecaPhase 1
33
Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3
77
AZD1236 + PlaceboAstraZenecaPhase 2
52
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3
77
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part BAstraZenecaPhase 1
33
AZD9668 + AZD9668 Placebo equivalentAstraZenecaPhase 2
52

Other Products from 4D Molecular Therapeutics

4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 3
69
4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 3
69
4D-150 IVT + Aflibercept IVTPhase 2
44
4D-310Phase 1/2
33
4D-150 IVT + Aflibercept IVTPhase 1/2
33